Cypralis and Gilead Sciences, Inc. agree on license terms for rights to certain macrocyclic inhibitors synthesised during a drug discovery collaboration between Gilead (Foster City, California) and Selcia Ltd.

In their endeavour to identify novel drugs for acute and chronic degenerative diseases, Cypralis (Cambridge, UK) have announced a license agreement with Gilead Sciences, Inc. for exclusive development and commercialization rights to certain jointly-owned macrocyclic inhibitors of peptide bond isomerases.  The compounds were discovered as part of an integrated drug discovery service provided by Selcia Ltd in support of Gilead’s (Foster City, California) activities within the liver disease arena. During the collaboration four jointly owned patents, one publication and two pre-clinical candidates were delivered.  Selcia’s rights under the agreement have been subsequently transferred to Cypralis.

Company News